Dulaglutide vs BPC-157 & TB-500 (Wolverine Stack)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Dulaglutide
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Full details →BPC-157 & TB-500 (Wolverine Stack)
Known as the 'Wolverine Stack,' this popular combination pairs two powerful healing peptides. BPC-157 and TB-500 work synergistically to promote tissue repair, reduce inflammation, and accelerate recovery from injuries.
Full details →Side-by-Side Comparison
| Aspect | Dulaglutide | BPC-157 & TB-500 (Wolverine Stack) |
|---|---|---|
| Mechanism | GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression. | BPC-157 upregulates growth factor expression and promotes angiogenesis, while TB-500 promotes cell migration and differentiation through actin regulation. Together, they enhance wound healing, reduce scar tissue formation, and support musculoskeletal recovery through complementary pathways. |
| Typical Dosage | Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response. | Typical research protocols: BPC-157 at 250-500mcg daily combined with TB-500 at 2-2.5mg twice weekly during loading phase, then 2mg every 2 weeks for maintenance. |
| Administration | Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens. | Both peptides administered via subcutaneous injection. Some protocols suggest injecting near injury sites for localized effects. Can be injected separately or as a pre-mixed blend. |
| Side Effects | Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration. | Generally well-tolerated. May include mild nausea, temporary fatigue, headache, or localized irritation at injection sites. |
| Best For |